By Fineline Cube 
China-based Ascletis Pharma Inc. (HKG: 1672) announced positive interim results from a Phase Ib study (NCT06679959) evaluating its investigational GLP-1R biased small molecule agonist, ASC30, in patients with obesity in the US. The study is a randomized, double-blinded, placebo-controlled trial involving a single subcutaneous (SQ) injection.
Drug Profile
ASC30 is a new chemical entity (NCE) with patent protection in the US and globally until 2044. The Phase Ib study demonstrated that ASC30 SQ injection was generally well tolerated, with a favorable safety profile.
Safety Results
- No Grade 3 or higher adverse events (AEs) were observed.
- The majority of gastrointestinal (GI)-related AEs were mild (Grade 1).
- No elevations of liver enzymes, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBL), were noted.
- Laboratory tests, vital signs, ECGs (including QTc intervals), and physical exams showed no abnormal findings.
- Most injection site reactions were mild, with no Grade 3 or higher reactions reported.-Fineline Info & Tech